HIGHLIGHTS
- who: Elīna Skuja and colleagues from the Pauls Stradins Clinical University Hospital, Riga, Latvia have published the article: Pathological Complete Remission in Young Colon Cancer Patient with a Large Liver Metastasis after FOLFOX-4/Bevacizumab Treatment - A Case Report, in the Journal: (JOURNAL)
- what: The first reason why it was decided in favor of antiVEGF antibody bevacizumab was the fact that it in combination with oxaliplatin-based regimen chemotherapy increase the rates of radical liver surgery , and the second one-was controversial role of the G61H mutation in the KRAS gene on resistance to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.